◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Astera Labs, Inc. (ALAB) EBITDA 2022–TTM

Name: Astera Labs, Inc. (ALAB) ebitda history 2022-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Astera Labs, Inc. annual ebitda for fiscal 2025 was $225 million, compared with -$79 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

ALAB Annual EBITDA

EBITDA (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31
EBITDA	—	$225M	($79M)	($21M)	($57M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALAB Quarterly EBITDA

EBITDA (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
EBITDA	—	$77M	$82M	$68M	$52M	$23M	$12M	$3M	($13M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

SKHY EBITDA — SK Hynix Inc. American Depositary Shares
ARM EBITDA — Arm Holdings plc American Depositary Shares
UMC EBITDA — United Microelectronics
CBRS EBITDA — Cerebras Systems Inc. Class A Common Stock
STM EBITDA — STMicroelectronics NV ADR
CRDO EBITDA — Credo Technology Group Holding Ltd

More ALAB metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All ALAB financial statements → Interactive ALAB charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.